SNAC is the absorption-enhancing technology that allows semaglutide to survive the harsh stomach environment and be absorbed orally, enabling the first FDA-approved oral GLP-1 receptor agonist.
First oral GLP-1 agonistSNAC-enabled oral semaglutide (Rybelsus) became the first FDA-approved oral GLP-1 receptor agonist in 2019, overcoming decades of challenges in oral peptide delivery
What the researchers found
SNAC technology works by three mechanisms: raising local gastric pH to protect semaglutide from acid degradation, shielding the peptide from enzymatic breakdown, and enhancing transcellular absorption across the stomach epithelium — together enabling clinically effective oral delivery of a GLP-1 receptor agonist.
Why it matters
The ability to take a GLP-1 receptor agonist as a daily pill instead of a weekly injection removes a major barrier to treatment. Many patients with type 2 diabetes are reluctant to start injectable therapies. SNAC technology represents a breakthrough in oral peptide delivery that could be applied to other peptide drugs beyond semaglutide.
The numbers in context
Oral semaglutide was FDA-approved in 2019. SNAC stands for sodium N-(8-[2-hydroxylbenzoyl] amino) caprylate.
How the study worked
Narrative review summarizing published studies on SNAC technology as an absorption enhancer, focusing on its application in the oral semaglutide formulation (Rybelsus). Covers preclinical absorption studies and clinical pharmacokinetic data.
Who was studied
Patients with type 2 diabetes using oral semaglutide
What this study cannot tell us
SNAC-based oral semaglutide has lower bioavailability compared to injectable semaglutide, requiring higher doses. The strict dosing requirements (empty stomach, minimal water, 30-minute fast) may reduce real-world adherence. This is a narrative review, not a systematic review with formal quality assessment of included studies.
How to read the evidence
Strong evidence base — this review summarizes well-established pharmacokinetic and clinical data supporting an already FDA-approved product with extensive Phase 3 trial data (PIONEER program).
When this study was published
Published in 2024, providing an up-to-date summary of SNAC technology after several years of real-world clinical use of oral semaglutide.
The bigger picture
Oral delivery of peptide therapeutics has been a major pharmaceutical challenge for decades. The success of SNAC with semaglutide proves that oral peptide delivery is achievable at therapeutic levels, potentially paving the way for oral formulations of other injectable peptide drugs — from insulin to growth hormone analogs.
Questions still open
- Can SNAC technology be successfully applied to other therapeutic peptides beyond semaglutide?
- Will next-generation absorption enhancers improve oral peptide bioavailability enough to match injectable formulations?
Common questions
Why can't you just swallow a regular semaglutide pill without SNAC?
Why do you have to take oral semaglutide on an empty stomach?
Read the original research
Current Understanding of Sodium N-(8-[2-Hydroxylbenzoyl] Amino) Caprylate (SNAC) as an Absorption Enhancer: The Oral Semaglutide Experience.
Clinical diabetes : a publication of the American Diabetes Association, 42(1), 74-86
Citation
Solis-Herrera, Carolina; Kane, Michael P; Triplitt, Curtis. (2024). Current Understanding of Sodium N-(8-[2-Hydroxylbenzoyl] Amino) Caprylate (SNAC) as an Absorption Enhancer: The Oral Semaglutide Experience.. Clinical diabetes : a publication of the American Diabetes Association, 42(1), 74-86. https://doi.org/10.2337/cd22-0118